KR20240038103A - Her2/neu 과발현 종양의 치료를 위한 조성물 및 방법 - Google Patents

Her2/neu 과발현 종양의 치료를 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20240038103A
KR20240038103A KR1020247007406A KR20247007406A KR20240038103A KR 20240038103 A KR20240038103 A KR 20240038103A KR 1020247007406 A KR1020247007406 A KR 1020247007406A KR 20247007406 A KR20247007406 A KR 20247007406A KR 20240038103 A KR20240038103 A KR 20240038103A
Authority
KR
South Korea
Prior art keywords
her2
neu
another embodiment
listeria
llo
Prior art date
Application number
KR1020247007406A
Other languages
English (en)
Korean (ko)
Inventor
바파 샤하비
아누 왈레챠
파울로 씨. 마시아그
이본느 패터슨
니콜라 메이슨
매튜 시비
Original Assignee
어드박시스, 인크.
더 트러스티스 오브 더 유니버시티 오브 펜실베니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/189,008 external-priority patent/US20150366955A9/en
Priority claimed from US14/268,436 external-priority patent/US20140234370A1/en
Application filed by 어드박시스, 인크., 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 filed Critical 어드박시스, 인크.
Publication of KR20240038103A publication Critical patent/KR20240038103A/ko

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103Receptors for growth factors
    • A61K39/001106Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247007406A 2014-02-25 2015-02-25 Her2/neu 과발현 종양의 치료를 위한 조성물 및 방법 KR20240038103A (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US14/189,008 US20150366955A9 (en) 2009-11-11 2014-02-25 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US14/189,008 2014-02-25
US14/268,436 2014-05-02
US14/268,436 US20140234370A1 (en) 2009-11-11 2014-05-02 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US201462076411P 2014-11-06 2014-11-06
US62/076,411 2014-11-06
KR1020167025517A KR20160122829A (ko) 2014-02-25 2015-02-25 Her2/neu 과발현 종양의 치료를 위한 조성물 및 방법
PCT/US2015/017559 WO2015130810A2 (en) 2014-02-25 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167025517A Division KR20160122829A (ko) 2014-02-25 2015-02-25 Her2/neu 과발현 종양의 치료를 위한 조성물 및 방법

Publications (1)

Publication Number Publication Date
KR20240038103A true KR20240038103A (ko) 2024-03-22

Family

ID=54009773

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247007406A KR20240038103A (ko) 2014-02-25 2015-02-25 Her2/neu 과발현 종양의 치료를 위한 조성물 및 방법
KR1020167025517A KR20160122829A (ko) 2014-02-25 2015-02-25 Her2/neu 과발현 종양의 치료를 위한 조성물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167025517A KR20160122829A (ko) 2014-02-25 2015-02-25 Her2/neu 과발현 종양의 치료를 위한 조성물 및 방법

Country Status (13)

Country Link
EP (1) EP3110942A4 (ru)
JP (1) JP2017507943A (ru)
KR (2) KR20240038103A (ru)
CN (1) CN106661538A (ru)
AU (1) AU2015223136A1 (ru)
BR (1) BR112016019534A2 (ru)
CA (1) CA2940646A1 (ru)
IL (1) IL247436A0 (ru)
MX (1) MX2016011114A (ru)
NZ (1) NZ723750A (ru)
RU (1) RU2016137834A (ru)
SG (1) SG11201607036XA (ru)
WO (1) WO2015130810A2 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
WO2012125551A1 (en) 2011-03-11 2012-09-20 Advaxis Listeria-based adjuvants
CN104411327A (zh) 2012-03-12 2015-03-11 阿德瓦希斯公司 李斯特菌疫苗治疗以后的抑制细胞功能抑制
US10143734B2 (en) 2014-02-18 2018-12-04 Advaxis, Inc. Biomarker directed multi-target immunotherapy
AU2015227163A1 (en) * 2014-03-05 2016-10-20 Advaxis, Inc. Methods and compositions for increasing a T-effector cell to regulatory T cell ratio
SG10202011841WA (en) 2014-04-24 2021-01-28 Advaxis Inc Recombinant listeria vaccine strains and methods of producing the same
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
RU2729116C2 (ru) 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
SG11201901979SA (en) 2016-11-30 2019-04-29 Advaxis Inc Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
MX2020003100A (es) 2017-09-19 2020-08-20 Advaxis Inc Composiciones y metodos para la liofilizacion de bacterias o cepas de listeria.
KR20200087143A (ko) 2017-10-10 2020-07-20 그릿스톤 온콜로지, 인코포레이티드 핫스팟을 이용한 신생항원 동정
JP2021503897A (ja) 2017-11-22 2021-02-15 グリットストーン オンコロジー インコーポレイテッド 新生抗原のためのジャンクションエピトープ提示の低減

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855320B2 (en) * 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
US9017660B2 (en) * 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors

Also Published As

Publication number Publication date
RU2016137834A (ru) 2018-03-29
AU2015223136A1 (en) 2016-09-22
WO2015130810A3 (en) 2016-01-28
NZ723750A (en) 2024-02-23
EP3110942A4 (en) 2017-08-30
MX2016011114A (es) 2017-02-20
IL247436A0 (en) 2016-11-30
CN106661538A (zh) 2017-05-10
WO2015130810A2 (en) 2015-09-03
KR20160122829A (ko) 2016-10-24
JP2017507943A (ja) 2017-03-23
CA2940646A1 (en) 2015-09-03
SG11201607036XA (en) 2016-09-29
BR112016019534A2 (pt) 2017-10-24
EP3110942A2 (en) 2017-01-04

Similar Documents

Publication Publication Date Title
KR20240038103A (ko) Her2/neu 과발현 종양의 치료를 위한 조성물 및 방법
JP6039669B2 (ja) Her2/neu発現腫瘍に対する薬剤の調製における弱毒化組換えリステリアの使用
JP5985397B2 (ja) 組換えリステリア株およびそれを含む免疫原性組成物
US20160361401A1 (en) Compositions and methods for the treatment of her2/neu over-expressing tumors
US20150297702A1 (en) Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
JP6182172B2 (ja) 異種抗原のための二重送達システム
US10016617B2 (en) Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
KR20170002552A (ko) Her-2-양성 암 치료용 병용 면역 치료 및 방사선 치료
KR20170092626A (ko) 재조합 리스테리아 균주의 병용 요법
KR20160130774A (ko) 바이오마커 지도된 다중-표적 면역치료
JP2017522027A (ja) 異種抗原融合タンパク質を発現する組み換え型リステリア株およびその使用方法
AU2016369580A1 (en) Listeria-based immunotherapy and methods of use thereof
JP6329211B2 (ja) 脳腫瘍または乳腺腫瘍の発症を遅延させるための医薬の製造における組換えリステリア株の使用
KR20220116191A (ko) 4-1bbl 아쥬반트화 재조합 변형 백시니아 바이러스 앙카라 (mva)의 의약적 용도
TW201707715A (zh) 用於治療her-2陽性癌症之組合免疫療法及放射線療法

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination